<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">sredob</journal-id><journal-title-group><journal-title xml:lang="ru">Здоровье населения и среда обитания – ЗНиСО</journal-title><trans-title-group xml:lang="en"><trans-title>Public Health and Life Environment – PH&amp;LE</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-5238</issn><issn pub-type="epub">2619-0788</issn><publisher><publisher-name>ФБУЗ ФЦГиЭ Роспотребнадзора</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35627/2219-5238/2023-31-4-40-46</article-id><article-id custom-type="elpub" pub-id-type="custom">sredob-1465</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВОПРОСЫ УПРАВЛЕНИЯ И СОЦИАЛЬНОЙ ГИГИЕНЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ISSUES OF MANAGEMENT AND SOCIAL HYGIENE</subject></subj-group></article-categories><title-group><article-title>Эпидемиологическая характеристика рака молочной железы на территории Воронежской области за период 2015–2019 гг.</article-title><trans-title-group xml:lang="en"><trans-title>Epidemiological Characteristics of Breast Cancer in the Voronezh Region in 2015–2019</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0247-5491</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Князева</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Knyazeva</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Князева Виктория Александровна – аспирант кафедры эпидемиологии </p><p>ул. Студенческая, д. 10, г. Воронеж, 394036</p></bio><bio xml:lang="en"><p>Victoria A. Knyazeva, postgraduate student, Department of Epidemiology</p><p>10 Studencheskaya Street, Voronezh, 394036</p></bio><email xlink:type="simple">vic.knz@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6952-0018</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамчик</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamchik</surname><given-names>N. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мамчик Николай Петрович – доктор медицинских наук, профессор, заведующий кафедры эпидемиологии</p><p>ул. Студенческая, д. 10, г. Воронеж, 394036</p></bio><bio xml:lang="en"><p>Nikolay P. Mamchik, Dr. Sci. (Med.), Professor, Head of the Department of Epidemiology</p><p>10 Studencheskaya Street, Voronezh, 394036</p></bio><email xlink:type="simple">mamchik1949@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5042-3739</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Габбасова</surname><given-names>Н. B.</given-names></name><name name-style="western" xml:lang="en"><surname>Gabbasova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Габбасова Наталия Вадимовна – доктор медицинских наук, профессор кафедры эпидемиологии </p><p>ул. Студенческая, д. 10, г. Воронеж, 394036</p></bio><bio xml:lang="en"><p>Nataliya V. Gabbasova, Dr. Sci. (Med.), Professor, Department of Epidemiology</p><p>10 Studencheskaya Street, Voronezh, 394036</p></bio><email xlink:type="simple">natalia_gabb@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1333-5638</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мошуров</surname><given-names>И. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Moshurov</surname><given-names>I. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мошуров Иван Петрович – доктор медицинских наук, доцент, заведующий кафедрой онкологии и специализированных хирургических дисциплин ИДПО ФГБОУ ВО «Воронежский государственный медицинский университет имени Н.Н. Бурденко»; главный врач БУЗ ВО «Воронежский областной клинический онкологический диспансер»</p><p>ул. Студенческая, д. 10, г. Воронеж, 394036; ул. Вайцеховского, д. 4, г. Воронеж, 394036</p></bio><bio xml:lang="en"><p>Ivan P. Moshurov, Dr. Sci. (Med.), Associate Professor, Head of the Department of Oncology and Specialized Surgical Disciplines, Voronezh State Medical University named after N.N. Burdenko; Chief Physician, Voronezh Regional Clinical Oncology Dispensary</p><p>10 Studencheskaya Street, Voronezh, 394036; 4 Vaitszekhovsky Street, Voronezh, 394036</p></bio><email xlink:type="simple">moshurov@vokod.vrn.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9234-1608</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Середа</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sereda</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Середа Анатолий Андреевич – заведующий организационно-методическим отделом</p><p>ул. Вайцеховского, д. 4, г. Воронеж, 394036</p></bio><bio xml:lang="en"><p>Anatoly A. Sereda, Head of Organizational and Methodical Department</p><p>4 Vaitszekhovsky Street, Voronezh, 394036</p></bio><email xlink:type="simple">omo@vokod.zdrav36.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Воронежский государственный медицинский университет имени Н.Н. Бурденко» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voronezh State Medical University named after N.N. Burdenko</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Воронежский государственный медицинский университет имени Н.Н. Бурденко» Минздрава России; &#13;
БУЗ ВО «Воронежской областной клинический онкологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voronezh State Medical University named after N.N. Burdenko; &#13;
Voronezh Regional Clinical Oncology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>БУЗ ВО «Воронежской областной клинический онкологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Voronezh Regional Clinical Oncology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>18</day><month>05</month><year>2023</year></pub-date><volume>31</volume><issue>4</issue><fpage>40</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Князева В.А., Мамчик Н.П., Габбасова Н.B., Мошуров И.П., Середа А.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Князева В.А., Мамчик Н.П., Габбасова Н.B., Мошуров И.П., Середа А.А.</copyright-holder><copyright-holder xml:lang="en">Knyazeva V.A., Mamchik N.P., Gabbasova N.V., Moshurov I.P., Sereda A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://zniso.fcgie.ru/jour/article/view/1465">https://zniso.fcgie.ru/jour/article/view/1465</self-uri><abstract><sec><title>Введение</title><p>Введение. Рак молочной железы – ведущее онкологическое заболевание среди женщин всего мира. Показатели заболеваемости неуклонно растут в глобальных масштабах, в Российской Федерации женщины с онкологией молочной железы составляют наибольшую часть от всех онкологических больных.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: анализ заболеваемости раком молочной железы в Воронежской области за период с 2015 по 2019 год.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Материалом послужили форма статистической отчетности № 7 «Сведения о злокачественных новообразованиях» за период с 2015 по 2019 г., статистический бюллетень «Численность населения Воронежской области по полу и возрастным группам». В исследование были включены женщины, проживающие на территории Воронежской области, с установленным диагнозом «рак молочной железы» за временной промежуток с 2015 по 2019 г. Расчет статистических параметров проводился при помощи пакета программ Microsoft Office Ехсеl 2016, уровень значимости р &lt; 0,05.</p></sec><sec><title>Результаты</title><p>Результаты. Заболеваемость раком молочной железы в Воронежской области за период 2015–2019 гг. имела умеренную тенденцию к росту: показатели первичной заболеваемости увеличились с 85,91 в 2015 г. до 93,89 на 100 тысяч женского населения в 2019 г.; показатели общей заболеваемости – с 904,5 до 1001,1 на 100 тысяч женского населения. Показатель смертности женщин от рака молочной железы в Воронежской области за анализируемый период характеризовался выраженной тенденцией к снижению – с 37,69 до 24,23 на 100 тысяч женского населения. Риск возникновения онкопатологии молочной железы у женщин достоверно возрастал с увеличением возраста (показатель ранговой корреляции r = 0,65, р &lt; 0,001), наиболее высокие уровни заболеваемости регистрировались у женщин в возрасте 60–74 лет. Наибольшее число злокачественных новообразований молочной железы выявлялось на II стадии патологического процесса. За исследованный период в структуре злокачественных новообразований молочной железы достоверно возрос удельный вес числа случаев выявления онкопатологии на I стадии заболевания – с 21,9 до 30,2 % (р &lt; 0,0001). Индекс достоверности учета рака молочной железы в Воронежской области имел тенденцию к снижению с 0,4 до 0,2.</p></sec><sec><title>Выводы</title><p>Выводы. Заболеваемость раком молочной железы среди женского населения Воронежской области за период 2015–2019 гг. характеризовалась умеренной тенденцией к росту. Выраженная тенденция к снижению показателей смертности, достоверное увеличение выявления патологии на I стадии заболевания, снижение индекса достоверности учета отражают качественные изменения в системе оказания медицинской помощи онкологическим больным, совершенствование системы учета онкологических больных в регионе.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Summary</title><p>Summary</p></sec><sec><title>Introduction</title><p>Introduction: Breast cancer is the most commonly occurring cancer in women worldwide. Incidence rates are continuously growing globally. In the Russian Federation, women with breast cancer make up the largest proportion of all cancer cases.</p></sec><sec><title>Objective</title><p>Objective: To analyze breast cancer statistics in the Voronezh Region for 2015–2019.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: We used data of the Statistical Reporting Form No. 7, Information about Malignant Neoplasms, for 2015–2019 and the statistical bulletin on Age and Sex Distribution of the Population of the Voronezh Region. Women living in the Voronezh Region and first diagnosed with breast cancer in 2015–2019 were included in the analysis. Statistical parameters were calculated using the Microsoft Office Excel 2016 software; the p-value of 0.05 or lower was considered statistically   significant.</p></sec><sec><title>Results</title><p>Results: Breast cancer rates in the Voronezh Region in 2015–2019 had a moderate upward trend: incidence rates rose from 85.91 in 2015 to 93.89 in 2019 while prevalence rates grew from 904.5 to 1,001.1 per 100,000 female population. The mortality from breast cancer, however, demonstrated a pronounced downward trend dropping from 37.69 to 24.23 per 100,000 female population over the same period. The risk of breast cancer in women rose significantly with age (r = 0.65, p &lt; 0.001) and the highest incidence rates were registered in the age group of 60 to 74 years. Most incident cases were diagnosed with stage II breast cancer. Yet, the proportion of new cases with stage I breast cancer grew statistically from 21.9 to 30.2 % (p &lt; 0.0001) in 2015–2019. The accounting information reliability index for the malignancy decreased from 0.4 to 0.2.</p></sec><sec><title>Conclusions</title><p>Conclusions: Breast cancer incidence and prevalence rates among the female population of the Voronezh Region showed a moderate upward trend in 2015–2019. A pronounced trend towards a decrease in mortality rates, a significant increase in the number of incident cases diagnosed with stage I of the neoplasm, and a decrease in the accounting reliability index reflect qualitative changes in the system of cancer care and improvements in cancer registration in the region.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>заболеваемость</kwd><kwd>смертность</kwd><kwd>структура</kwd><kwd>индекс достоверности учета</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>incidence</kwd><kwd>mortality</kwd><kwd>structure</kwd><kwd>accounting information reliability index</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Starinsky VV, Shakhzadova AO, eds. [Cancer Treatment in Russia in 2021.] Moscow: MNIOI im. P.A. Herzen – Branch NMITs Radiology Publ.; 2022. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660</mixed-citation><mixed-citation xml:lang="en">Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Аксель Е.М., Виноградова Н.Н. Статистика злокачественных новообразований женских репродуктивных органов // Онкогинекология. 2018. № 3. С. 64–78. doi: 10.52313/22278710_2018_3_6</mixed-citation><mixed-citation xml:lang="en">Aksel EM, Vinogradova NN. Statistics of malignant neoplasms of female reproductive organs. Onkoginekologiya. 2018;(3(27)):64-78. (In Russ.) doi: 10.52313/22278710_2018_3_64</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394424. doi: 10.3322/caac.21492</mixed-citation><mixed-citation xml:lang="en">Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394424. doi: 10.3322/caac.21492</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847–860. doi: 10.1016/S0140-6736(16)31392-7</mixed-citation><mixed-citation xml:lang="en">Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847–860. doi: 10.1016/S0140-6736(16)31392-7</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Liu FC, Lin HT, Kuo CF, See LC, Chiou MJ, Yu HP. Epidemiology and survival outcome of breast cancer in a nationwide study. Oncotarget. 2017;8(10):16939-16950. doi: 10.18632/oncotarget.15207</mixed-citation><mixed-citation xml:lang="en">Liu FC, Lin HT, Kuo CF, See LC, Chiou MJ, Yu HP. Epidemiology and survival outcome of breast cancer in a nationwide study. Oncotarget. 2017;8(10):16939-16950. doi: 10.18632/oncotarget.15207</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rezaianzadeh A, Jalali M, Maghsoudi A, Mokhtari AM, Azgomi SH, Dehghani SL. The overall 5-year survival rate of breast cancer among Iranian women: A systematic review and meta-analysis of published studies. Breast Dis. 2017;37(2):63-68. doi: 10.3233/BD-160244</mixed-citation><mixed-citation xml:lang="en">Rezaianzadeh A, Jalali M, Maghsoudi A, Mokhtari AM, Azgomi SH, Dehghani SL. The overall 5-year survival rate of breast cancer among Iranian women: A systematic review and meta-analysis of published studies. Breast Dis. 2017;37(2):63-68. doi: 10.3233/BD-160244</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ogiya R, Niikura N, Kumamaru H, et al. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. Breast Cancer Res Treat. 2020;184(2):585-596. doi: 10.1007/s10549-020-05869-y</mixed-citation><mixed-citation xml:lang="en">Ogiya R, Niikura N, Kumamaru H, et al. Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study. Breast Cancer Res Treat. 2020;184(2):585-596. doi: 10.1007/s10549-020-05869-y</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953. doi: 10.1002/ijc.31937</mixed-citation><mixed-citation xml:lang="en">Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953. doi: 10.1002/ijc.31937</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Escala-Garcia M, Morra A, Canisius S, et al. Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. BMC Med. 2020;18(1):327. doi: 10.1186/s12916-020-01797-2</mixed-citation><mixed-citation xml:lang="en">Escala-Garcia M, Morra A, Canisius S, et al. Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. BMC Med. 2020;18(1):327. doi: 10.1186/s12916-020-01797-2</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kashyap D, Pal D, Sharma R, et al. Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Res Int. 2022;2022:9605439. doi: 10.1155/2022/9605439</mixed-citation><mixed-citation xml:lang="en">Kashyap D, Pal D, Sharma R, et al. Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Res Int. 2022;2022:9605439. doi: 10.1155/2022/9605439</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">de Boer MC, Wörner EA, Verlaan D, van Leeuwen PAM. The mechanisms and effects of physical activity on breast cancer. Clin Breast Cancer. 2017;17(4):272-278. doi: 10.1016/j.clbc.2017.01.006</mixed-citation><mixed-citation xml:lang="en">de Boer MC, Wörner EA, Verlaan D, van Leeuwen PAM. The mechanisms and effects of physical activity on breast cancer. Clin Breast Cancer. 2017;17(4):272-278. doi:  10.1016/j.clbc.2017.01.006</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ramírez K, Acevedo F, Herrera ME, Ibáñez C, Sánchez C. [Physical activity and breast cancer.] Rev Med Chil. 2017;145(1):75-84. (In Span.) doi: 10.4067/S003498872017000100011</mixed-citation><mixed-citation xml:lang="en">Ramírez K, Acevedo F, Herrera ME, Ibáñez C, Sánchez C. [Physical activity and breast cancer.] Rev Med Chil. 2017;145(1):75-84. (In Span.) doi: 10.4067/S003498872017000100011</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Гатуева Ф.С., Любченко Л.Н., Малыгин С.Е. Наследственная форма рака молочной железы: современное состояние проблемы. Клиническая практика. 2020. Т. 11. № 1. С. 103–111. doi: 10.17816/clinpract18964</mixed-citation><mixed-citation xml:lang="en">Gatueva FS, Lyubchenko LN, Malygin SE. Hereditary breast cancer: Present status of problem. Klinicheskaya Praktika. 2020;11(1):103-111. (In Russ.) doi: 10.17816/clinpract18964</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50 and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res. 2011;13(1):R20. doi: 10.1186/bcr2832</mixed-citation><mixed-citation xml:lang="en">Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50 and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res. 2011;13(1):R20. doi: 10.1186/bcr2832</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Siddig A, Tengku Din TADA, Mohd Nafi SN, Yahya MM, Sulong S, Wan Abdul Rahman WF. The unique biology behind the early onset of breast cancer. Genes (Basel). 2021;12(3):372. doi: 10.3390/genes12030372</mixed-citation><mixed-citation xml:lang="en">Siddig A, Tengku Din TADA, Mohd Nafi SN, Yahya MM, Sulong S, Wan Abdul Rahman WF. The unique biology behind the early onset of breast cancer. Genes (Basel). 2021;12(3):372. doi: 10.3390/genes12030372</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Criscitiello C, Corti C. Breast cancer genetics: diagnostics and treatment. Genes (Basel). 2022;13(9):1593. doi: 10.3390/genes13091593</mixed-citation><mixed-citation xml:lang="en">Criscitiello C, Corti C. Breast cancer genetics: diagnostics and treatment. Genes (Basel). 2022;13(9):1593. doi: 10.3390/genes13091593</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández MF, Reina-Pérez I, Astorga JM, Rodríguez-Carrillo A, Plaza-Díaz J, Fontana L. Breast cancer and its relationship with the microbiota. Int J Environ Res Public Health. 2018;15(8):1747. doi: 10.3390/ijerph15081747</mixed-citation><mixed-citation xml:lang="en">Fernández MF, Reina-Pérez I, Astorga JM, Rodríguez-Carrillo A, Plaza-Díaz J, Fontana L. Breast cancer and its relationship with the microbiota. Int J Environ Res Public Health. 2018;15(8):1747. doi: 10.3390/ijerph15081747</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Eliassen AH, Liao X, Rosner B, Tamimi RM, Tworoger SS, Hankinson SE. Plasma carotenoids and risk of breast cancer over 20 y of follow-up. Am J Clin Nutr. 2015;101(6):1197– 1205. doi: 10.3945/ajcn.114.105080</mixed-citation><mixed-citation xml:lang="en">Eliassen AH, Liao X, Rosner B, Tamimi RM, Tworoger SS, Hankinson SE. Plasma carotenoids and risk of breast cancer over 20 y of follow-up. Am J Clin Nutr. 2015;101(6):1197– 1205. doi: 10.3945/ajcn.114.105080</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Huss L, Butt ST, Borgquist S, et al. Vitamin D receptor expression in invasive breast tumors and breast cancer survival. Breast Cancer Res. 2019;21(1):84. doi: 10.1186/s13058-019-1169-1</mixed-citation><mixed-citation xml:lang="en">Huss L, Butt ST, Borgquist S, et al. Vitamin D receptor expression in invasive breast tumors and breast cancer survival. Breast Cancer Res. 2019;21(1):84. doi: 10.1186/s13058-019-1169-1</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Мерабишвили В.М. Приоритетные задачи совершенствования онкологической статистики в России // Биосфера. 2018. Т. 10. № 2. С. 176-204. doi: 10.24855/BIOSFERA.V10I2.443</mixed-citation><mixed-citation xml:lang="en">Merabishvili VM. Priority tasks of improving cancer registry in Russia. Biosfera. 2018;10(2):176-204. (In Russ.) doi: 10.24855/BIOSFERA.V10I2.443</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15-23. doi: 10.1016/j.breast.2022.08.010</mixed-citation><mixed-citation xml:lang="en">Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15-23. doi: 10.1016/j.breast.2022.08.010</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
